Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034329485> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2034329485 endingPage "A571" @default.
- W2034329485 startingPage "A571" @default.
- W2034329485 abstract "The value of ranibizumab as compared to standard care (laser photocoagulation in BRVO and observation in CRVO) was assessed within the framework of a cost-utility analysis (CUA) from the Canadian health care and societal perspectives. Cost-utility of ranibizumab to the Canadian health care system was analyzed using a Markov model that followed a cohort of 66 or 68 year old patients (with BRVO or CRVO) over a lifetime time horizon. The model included 8 heath states as defined by best corrected visual acuity (BCVA) and 1 absorbing state for death. Year 1 health state transitions were based on data from the BRAVO and CRUISE trials, while year 2 transitions were based on data from the HORIZON extension trial. From year 3 onwards, health state transitions were based on fixed probabilities of maintaining or worsening BCVA. Health state utilities were derived from both the literature and a Canadian utility study in RVO patients. Resource use and costs were collected from clinical trials, published literature, and standard Canadian sources. Costs and outcomes were discounted at 5% as recommended by Canadian guidelines. From the health care perspective, patients receiving ranibizumab for BRVO accrued an additional 0.22 quality-adjusted life years (QALYs) with a total estimated incremental cost of CAD$8,080, resulting in $36,725 per QALY gained. In CRVO, 0.41 QALYs and $11,466 were estimated, resulting in $28,046 per QALY gained. From the societal perspective, considering costs related to productivity losses, the analyses resulted in an incremental cost per QALY gained of $11,266 for BRVO and $2,103 for CRVO. Compared to standard care (laser photocoagulation in BRVO and observation in CRVO), ranibizumab shows cost-effectiveness within commonly accepted cost per QALY thresholds from both the health care and societal perspectives." @default.
- W2034329485 created "2016-06-24" @default.
- W2034329485 creator A5000365235 @default.
- W2034329485 creator A5003725323 @default.
- W2034329485 creator A5011603375 @default.
- W2034329485 creator A5028450181 @default.
- W2034329485 creator A5085268308 @default.
- W2034329485 date "2012-11-01" @default.
- W2034329485 modified "2023-09-30" @default.
- W2034329485 title "PSS19 Economic Evaluation of Ranibizumab for the Treatment of Macular Edema Secondary to Branch and Central Retinal Vein Occlusion in Canada" @default.
- W2034329485 doi "https://doi.org/10.1016/j.jval.2012.08.2066" @default.
- W2034329485 hasPublicationYear "2012" @default.
- W2034329485 type Work @default.
- W2034329485 sameAs 2034329485 @default.
- W2034329485 citedByCount "1" @default.
- W2034329485 countsByYear W20343294852016 @default.
- W2034329485 crossrefType "journal-article" @default.
- W2034329485 hasAuthorship W2034329485A5000365235 @default.
- W2034329485 hasAuthorship W2034329485A5003725323 @default.
- W2034329485 hasAuthorship W2034329485A5011603375 @default.
- W2034329485 hasAuthorship W2034329485A5028450181 @default.
- W2034329485 hasAuthorship W2034329485A5085268308 @default.
- W2034329485 hasBestOaLocation W20343294851 @default.
- W2034329485 hasConcept C112930515 @default.
- W2034329485 hasConcept C118487528 @default.
- W2034329485 hasConcept C119767625 @default.
- W2034329485 hasConcept C141071460 @default.
- W2034329485 hasConcept C194828623 @default.
- W2034329485 hasConcept C2776694085 @default.
- W2034329485 hasConcept C2777802072 @default.
- W2034329485 hasConcept C2778257484 @default.
- W2034329485 hasConcept C2778844676 @default.
- W2034329485 hasConcept C2780261187 @default.
- W2034329485 hasConcept C2780347916 @default.
- W2034329485 hasConcept C2781100027 @default.
- W2034329485 hasConcept C3019080777 @default.
- W2034329485 hasConcept C64332521 @default.
- W2034329485 hasConcept C71924100 @default.
- W2034329485 hasConceptScore W2034329485C112930515 @default.
- W2034329485 hasConceptScore W2034329485C118487528 @default.
- W2034329485 hasConceptScore W2034329485C119767625 @default.
- W2034329485 hasConceptScore W2034329485C141071460 @default.
- W2034329485 hasConceptScore W2034329485C194828623 @default.
- W2034329485 hasConceptScore W2034329485C2776694085 @default.
- W2034329485 hasConceptScore W2034329485C2777802072 @default.
- W2034329485 hasConceptScore W2034329485C2778257484 @default.
- W2034329485 hasConceptScore W2034329485C2778844676 @default.
- W2034329485 hasConceptScore W2034329485C2780261187 @default.
- W2034329485 hasConceptScore W2034329485C2780347916 @default.
- W2034329485 hasConceptScore W2034329485C2781100027 @default.
- W2034329485 hasConceptScore W2034329485C3019080777 @default.
- W2034329485 hasConceptScore W2034329485C64332521 @default.
- W2034329485 hasConceptScore W2034329485C71924100 @default.
- W2034329485 hasIssue "7" @default.
- W2034329485 hasLocation W20343294851 @default.
- W2034329485 hasOpenAccess W2034329485 @default.
- W2034329485 hasPrimaryLocation W20343294851 @default.
- W2034329485 hasRelatedWork W2053282839 @default.
- W2034329485 hasRelatedWork W2056912245 @default.
- W2034329485 hasRelatedWork W2093993639 @default.
- W2034329485 hasRelatedWork W2160034796 @default.
- W2034329485 hasRelatedWork W2228229668 @default.
- W2034329485 hasRelatedWork W2298380539 @default.
- W2034329485 hasRelatedWork W2321859266 @default.
- W2034329485 hasRelatedWork W3091585714 @default.
- W2034329485 hasRelatedWork W3158593454 @default.
- W2034329485 hasRelatedWork W3164501075 @default.
- W2034329485 hasVolume "15" @default.
- W2034329485 isParatext "false" @default.
- W2034329485 isRetracted "false" @default.
- W2034329485 magId "2034329485" @default.
- W2034329485 workType "article" @default.